AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease - AC Immune ( NASDAQ:ACIU )
Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD FDA Fast Track designation granted in July for ACI-35.030 ( now "JNJ-2056" ) ...
| Ticker |
Sentiment |
Impact |
|
ACIU
|
Neutral
|
29 %
|
|
JNJ
|
Neutral
|
32 %
|
